About trifluridin e
Antineoplastic nucleoside analogue combination
Used for
- Treats metastatic colorectal cancer after other treatments have stopped working or are unsuitable.
- Treats metastatic gastric or gastroesophageal junction cancer after prior treatments.
Usual adult dose
Usually 35 mg/m² by mouth twice daily on days 1–5 and 8–12 of each 28-day cycle, with food; maximum 80 mg per dose.
Common side effects
- Low blood cell counts, including neutropenia and anemia
- Nausea, vomiting, diarrhea, or reduced appetite
- Fatigue
- Fever or infections
Important warnings
- Can cause severe bone marrow suppression; blood counts need monitoring.
- Seek urgent assessment for fever, unusual bleeding, or signs of infection.
- Use effective contraception during treatment; may harm an unborn baby.
- Tablets contain trifluridine and tipiracil; the dose is based on trifluridine.
Pregnancy
May cause fetal harm. Avoid use during pregnancy; effective contraception is needed during treatment and for six months afterward for women, and three months for men with partners who could become pregnant.
Breastfeeding
Do not breastfeed during treatment or for one day after the last dose.
Interactions
- Medicines that affect nucleoside transporters, such as zidovudine, may reduce trifluridine effectiveness.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.